Dysfunctional Uterine Bleeding in Pediatrics Medication

  • Author: Germaine L Defendi, MD, MS, FAAP; Chief Editor: Andrea L Zuckerman, MD   more...
 
Updated: Jul 13, 2011
 

Medication Summary

Pharmacotherapy is aimed at preventing medical complications of dysfunctional uterine bleeding (DUB).

  • Hormone therapy (eg, estrogen, combination estrogen/progestin)[14]
  • Antiprostaglandins
  • Antifibrinolytics[15]
  • Iron supplements

Experimental therapies (eg, gonadotropin-releasing hormone [GnRH] agonists) may have a limited place in the treatment of unresponsive bleeding; however, insufficient evidence currently exists to support their routine use.

Next

Estrogens

Class Summary

Anovulatory bleeding occurs as the hyperproliferative endometrium, lacking a progesterone effect, outgrows its estrogen supply, leading to irregular sloughing. Rapid return of adequate estrogen levels is the quickest way to decrease bleeding. Estrogens alone are primarily used for acute DUB when rapid control of the bleeding is required.

Estrogen, conjugated (Premarin)

 

Administered PO, IM, or IV. Studies have demonstrated that similar blood levels are achieved at the same rate by any route. Parenteral therapy is reserved for patients who are unable to tolerate PO intake. Equivalent doses of other forms of estrogen (eg, estradiol, esterified estrogens, ethinyl estradiol, estropipate) are likely to be equally effective although clinical studies are lacking. Only the conjugated estrogens are approved by the FDA for this indication.

Previous
Next

Progestins

Class Summary

Individually, progestins are used to stabilize an estrogen-primed endometrium and are administered in a cyclic fashion. Because the pathophysiology of DUB is based on a relative estrogen deficiency, progestins alone should not be the first-line treatment for acute bleeding. Progestins should be administered along with estrogens, and this combination is discussed under PO contraceptive pills.

Continuous use of high-dose progestins, orally or in a depot form, can induce endometrial atrophy and amenorrhea. This approach is useful for preventing future blood loss while correcting a significant anemia or when combination contraceptive pills do not achieve adequate control of bleeding.

Medroxyprogesterone (Amen, Provera, Depo-Provera)

 

May be administered PO, in a cyclic or continuous fashion, or as a parenteral depot formulation. When managing acute and heavy uterine bleeding, should be administered concurrently with an estrogen preparation. Progestins alone do not address the underlying pathophysiology of a hyperproliferative endometrium that has outgrown its estrogen supply.

Norethindrone (Aygestin, Micronor)

 

Administered PO in a cyclic or continuous fashion. When managing acute and heavy uterine bleeding, should be administered concurrently with estrogen. Progestins alone do not address the underlying pathophysiology of a hyperproliferative endometrium that has outgrown its estrogen supply.

Previous
Next

Oral contraceptive agents

Class Summary

Oral contraceptive agents or oral contraceptive pills (OCPs) provide a convenient method of rapidly delivering high-dose combinations of estrogen and progestin. The monophasic preparations offer the best opportunity for creating a stable endocrine environment. Most of the modern products contain 20, 30, or 35 mcg of ethinyl estradiol in combination with norethindrone or one of the second- or third-generation progestins. For all practical purposes, they are essentially equivalent.

Ethinyl estradiol and desogestrel (Desogen)

 

This is one example of an OCP preparation. When treating light-flow irregular bleeding, OCPs are administered in the usual contraceptive fashion (ie, 1 tab PO qd for 21 d of a typical 28-d cycle). Treatment of acute heavy uterine bleeding, multiple tab are administered PO each day and then tapered once the heavy flow has ceased. If significant anemia is present, the placebo phase (ie, days 22-28) may be omitted for several mo.

Previous
Next

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Class Summary

Studies have demonstrated a prostaglandin imbalance in women with menorrhagia and a reduction in menstrual flow with administration of NSAIDs. Several drugs in this category should have similar efficacy.

Ibuprofen (Motrin, Advil, Ibuprin)

 

A classic example of this category of medications. For best efficacy, start the NSAID prior to the onset of flow. Have analgesic, anti-inflammatory, and antipyretic activities. Mechanism of action is nonselective inhibition of cyclooxygenases 1 and 2, resulting in reduced synthesis of prostaglandins and thromboxanes.

Previous
Next

Antifibrinolytic agents

Class Summary

These agents inhibit fibrinolysis via inhibition of plasminogen activator substances, to a lesser degree, through antiplasmin activity.

Aminocaproic acid (Amicar)

 

Used for acute heavy uterine bleeding in patients with increased fibrinolytic activity. Discontinued once bleeding has stopped.

Previous
Next

Iron salts

Class Summary

These are used to replenish iron stores lost during acute or chronic hemorrhage. The body stores iron in compounds called ferritin and hemosiderin for future use in the production of hemoglobin. Iron absorption is a variable of the existing body iron stores, the form and quantity in foods, and the combination of foods in the diet. The ferrous form of inorganic iron is more readily absorbed.

Ferrous sulfate (Feosol, Slow FE, Feostat)

 

This is the most common medication for iron therapy though several other formulations are available.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Germaine L Defendi, MD, MS, FAAP  Associate Clinical Professor, Department of Pediatrics, Olive View-UCLA Medical Center

Germaine L Defendi, MD, MS, FAAP is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Specialty Editor Board

Elizabeth Alderman, MD  Director of Fellowship Training Program, Director of Adolescent Ambulatory Service, Professor of Clinical Pediatrics, Department of Pediatrics, Division of Adolescent Medicine, Albert Einstein College of Medicine and Children's Hospital at Montefiore

Elizabeth Alderman, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, North American Society for Pediatric and Adolescent Gynecology, and Society for Adolescent Medicine

Disclosure: Merck Honoraria Speaking and teaching

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Wayne Wolfram, MD, MPH  Associate Professor, Department of Emergency Medicine, Mercy St Vincent Medical Center

Wayne Wolfram, MD, MPH is a member of the following medical societies: American Academy of Emergency Medicine, American Academy of Pediatrics, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Paul D Petry, DO, FACOP, FAAP  Consulting Staff, Freeman Pediatric Care, Freeman Health System

Paul D Petry, DO, FACOP, FAAP is a member of the following medical societies: American Academy of Osteopathy, American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association

Disclosure: Nothing to disclose.

Chief Editor

Andrea L Zuckerman, MD  Assistant Professor of Obstetrics/Gynecology and Pediatrics, Tufts University School of Medicine; Division Director, Pediatric and Adolescent Gynecology, Tufts Medical Center

Andrea L Zuckerman, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, Association of Professors of Gynecology and Obstetrics, Massachusetts Medical Society, North American Society for Pediatric and Adolescent Gynecology, and Society for Adolescent Medicine

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors Tod C Aeby, MD, and LeighAnn C Frattarelli, MD, MPH,to the development and writing of this article.

References
  1. Bravender T, Emans SJ. Menstrual disorders. Dysfunctional uterine bleeding. Pediatr Clin North Am. Jun 1999;46(3):545-53, viii. [Medline].

  2. Coupey SM, Ahlstrom P. Common menstrual disorders. Pediatr Clin North Am. Jun 1989;36(3):551-71. [Medline].

  3. Lavin C. Dysfunctional uterine bleeding in adolescents. Curr Opin Pediatr. Aug 1996;8(4):328-32. [Medline].

  4. Minjarez DA, Bradshaw KD. Abnormal uterine bleeding in adolescents. Obstet Gynecol Clin North Am. Mar 2000;27(1):63-78. [Medline].

  5. Strickland J, Gibson EJ, Levine SB. Dysfunctional uterine bleeding in adolescents. J Pediatr Adolesc Gynecol. Feb 2006;19(1):49-51. [Medline].

  6. Collins J, Crosignani PG. Endometrial bleeding. Hum Reprod Update. Sep-Oct 2007;13(5):421-31. [Medline].

  7. Anderson SE, Must A. Interpreting the continued decline in the average age at menarche: results from two nationally representative surveys of U.S. girls studied 10 years apart. J Pediatr. Dec 2005;147(6):753-60. [Medline].

  8. Austin SB, Ziyadeh NJ, Vohra S, Forman S, Gordon CM, Prokop LA. Irregular menses linked to vomiting in a nonclinical sample: findings from the National Eating Disorders Screening Program in high schools. J Adolesc Health. May 2008;42(5):450-7. [Medline].

  9. Toth M, Patton DL, Esquenazi B, Shevchuk M, Thaler H, Divon M. Association between Chlamydia trachomatis and abnormal uterine bleeding. Am J Reprod Immunol. May 2007;57(5):361-6. [Medline].

  10. National Heart Lung and Blood Institute (NHLBI). The Diagnosis, Evaluation and Management of von Willebrand Disease -- 2008 Clinical Practice Guidelines. National Institutes of Health. 2008;[Full Text].

  11. [Guideline] ACOG. Management of Anovulatory Bleeding. 2008 Compendium of Selected Publications. 2000;14:1049-56. [Full Text].

  12. Casablanca Y. Management of dysfunctional uterine bleeding. Obstet Gynecol Clin North Am. Jun 2008;35(2):219-34, viii. [Medline].

  13. Stabinsky SA, Einstein M, Breen JL. Modern treatments of menorrhagia attributable to dysfunctional uterine bleeding. Obstet Gynecol Surv. Jan 1999;54(1):61-72. [Medline].

  14. Rajput R, Dhuan J, Agarwal S, Gahlaut PS. Central venous sinus thrombosis in a young woman taking norethindrone acetate for dysfunctional uterine bleeding: case report and review of literature. J Obstet Gynaecol Can. Aug 2008;30(8):680-3. [Medline].

  15. Gultekin M, Diribas K, Buru E, Gökçeoglu MA. Role of a non-hormonal oral anti-fibrinolytic hemostatic agent (tranexamic acid) for management of patients with dysfunctional uterine bleeding. Clin Exp Obstet Gynecol. 2009;36(3):163-5. [Medline].

Previous
Next
 
The menstrual cycle.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.